BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 33796107)

  • 1. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells.
    Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM
    Front Immunol; 2021; 12():641521. PubMed ID: 33796107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
    Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
    Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
    Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
    Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
    Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.
    Clémenceau B; Vivien R; Pellat C; Foss M; Thibault G; Vié H
    MAbs; 2013; 5(4):587-94. PubMed ID: 23770975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
    Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
    J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII-Fc Activates Natural Killer Cells
    Lagassé HAD; Hopkins LB; Jankowski W; Jacquemin MG; Sauna ZE; Golding B
    Front Immunol; 2021; 12():692157. PubMed ID: 34262568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
    Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
    MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonistic effects of anti-CD2 and anti-CD16 antibodies on human natural killer killing.
    Uggla CK; Geisberg M; Jondal M; Knowles RW
    Scand J Immunol; 1989 May; 29(5):507-15. PubMed ID: 2567053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R; Schlom J; Hodge JW
    J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
    Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
    Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
    Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
    Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
    Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity.
    Grier JT; Forbes LR; Monaco-Shawver L; Oshinsky J; Atkinson TP; Moody C; Pandey R; Campbell KS; Orange JS
    J Clin Invest; 2012 Oct; 122(10):3769-80. PubMed ID: 23006327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR.
    van de Griend RJ; Bolhuis RL; Stoter G; Roozemond RC
    J Immunol; 1987 May; 138(10):3137-44. PubMed ID: 2952709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer (NK) activity in human responders and nonresponders to stimulation by anti-CD16 antibodies.
    Galatiuc C; Gherman M; Metes D; Sulica A; DeLeo A; Whiteside TL; Herberman RB
    Cell Immunol; 1995 Jul; 163(2):167-77. PubMed ID: 7606790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells.
    Srpan K; Ambrose A; Karampatzakis A; Saeed M; Cartwright ANR; Guldevall K; De Matos GDSC; Önfelt B; Davis DM
    J Cell Biol; 2018 Sep; 217(9):3267-3283. PubMed ID: 29967280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
    Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
    BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Targeting Anti-CD20 Antibodies Mediate
    Capuano C; Battella S; Pighi C; Franchitti L; Turriziani O; Morrone S; Santoni A; Galandrini R; Palmieri G
    Front Immunol; 2018; 9():1031. PubMed ID: 29867997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.